Full Year 2024 Indivior PLC Earnings Call Transcript
Key Points
- Indivior PLC (INDV) achieved a 20% net revenue growth for its primary product, SUBLOCADE, in 2024.
- The company implemented cost reductions of over $100 million annually, contributing to more than $50 million in savings.
- Indivior PLC (INDV) resolved certain legacy litigation, reducing enterprise risk and enhancing financial flexibility.
- The company is optimistic about FDA approval for label changes to SUBLOCADE, which could improve its competitive positioning.
- Indivior PLC (INDV) is investing in commercial strategies to increase awareness of SUBLOCADE, aiming to expand the market and increase market share.
- Indivior PLC (INDV) faced challenges in 2024, including competition in the US long-acting injectable category and the discontinuation of its schizophrenia treatment, PERSERIS.
- The company expects a sharp decline in net revenue from SUBOXONE Film in 2025 due to intensified competitive generic pricing activity.
- SUBLOCADE's net revenue is anticipated to remain relatively unchanged in 2025 due to competitive dynamics and funding challenges in the justice system.
- Indivior PLC (INDV) projects a decline in total net revenue and adjusted operating profit for 2025 compared to 2024.
- The company is not currently considering business development or a return of capital to shareholders, focusing instead on reinvesting in SUBLOCADE and completing clinical studies.
Good day and thank you for standing by. Welcome to the Indivior PLC, full year results, 2024.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to your host for today's call, Jason Thompson, Head of Investor Relations. Please go ahead.
Thanks, Sarah. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties and that actual results may differ materially. We list the factors that may cause our results to be materially different on slide 2 of our presentation. These statements are based on current information and beliefs, and we disclaim any obligation to update them except where required by law. We also may refer to non-gap measures, the reconciliations for which may also be found in the appendix of our presentation that is now posted on our website at indivior.com. I'll now turn the call over to Mark
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
